Hisamitsu Pharmaceutical Co., Inc. Email Format

Pharmaceutical ManufacturingJapan501-1000 Employees

Hisamitsu Pharmaceutical Co., Inc. is a Japanese pharmaceutical manufacturer with roots dating back to 1834. It concentrates on external analgesic and anti-inflammatory products, such as medicated plasters, gels, and sprays. The company operates in Japan and extends its capabilities internationally through its U.S. subsidiary, Noven, which develops transdermal therapies. A notable development is the XELSTRYM transdermal system (dextroamphetamine) for ADHD, the first and only FDA-approved amphetamine patch, with availability to prescribers anticipated in early 2023.

Its product portfolio includes topical analgesics such as Air Salonpas Z, launched in 2021 for muscle pain, bruises, and sprains, illustrating its emphasis on non-oral relief options. The firm has pursued broader delivery technologies through Noven and related initiatives and has explored applications beyond everyday medicine via the Fixpace program, addressing challenges of living in space and on Earth.

Get verified Hisamitsu Pharmaceutical Co., Inc. emails free

Company overview Employee directory